Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic CD19-CAR-NK Cells in Refractory Myasthenia Gravis
NCT07243366Phase 1Not yet recruiting
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
- Start
- Nov 2025
- Primary completion
- Jun 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 1, open-label, single-arm trial of CD19-CAR-NK cells in myasthenia gravis (MG), sponsored by Guangdong ProCapZoom Biosciences Co., Ltd. Primary endpoint: Adverse Events at 1 year. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
CD19-CAR-NK cells
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07243366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07243366.